Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTI-2341
- Development stage
- Preclinical
- Lead developer
- Trillium Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TTI-2341 is a second-generation, brain-penetrant, covalent small molecule inhibitor of the epidermal growth factor receptor (EGFR). Developed by Trillium Therapeutics (acquired by Pfizer), it is designed to target both wild-type and mutant forms of EGFR, including the resistance-associated L858R and T790M variants. The compound is specifically engineered for high central nervous system (CNS) penetration, demonstrating superior oral bioavailability (86%) and significantly higher brain exposure compared to earlier inhibitors like afatinib. It is primarily being investigated for the treatment of glioblastoma multiforme (GBM) and brain metastases originating from non-small cell lung cancer (NSCLC).
02
Targets
Beyond the preview
Go deeper on TTI-2341.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTI-2341.